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We present a case of Torsade de Pointes secondary to multiple factors including patient susceptibility and iatrogenic inﬂuences.
Contributing causes are presented, and the approach to treatment is discussed.
1.CaseReport
A 50-year-old male with a past history of HIV infection,
acquired immune deﬁciency syndrome (AIDS), pneumocys-
tis carinii pneumonia, hepatitis C, and hepatoma (postra-
diofrequency ablation) presented to the emergency room
for weakness and syncope which occurred in the bathroom
whilestrainingtodefecate.Hedeniedpalpitation,chestpain,
or shortness of breath prior to losing consciousness. There
was no history of seizure disorder. The following day while
walking to the hospital, he developed lightheadedness again
which was associated with diaphoresis and had to hold onto
a pole for support for two minutes before feeling able to
continue. There was a history of cocaine and IV heroin abuse
(discontinued two years ago).
Prehospital medications included lamivudine/zidovud-
ine, atazanavir, trimethoprim/sulfamethoxazole, and meth-
adone. He was on antiretroviral drugs for 10 years, and the
methadone dosage was increased to 40mg/day two months
prior to this presentation. On admission in the ER, he
had a regularly irregular pulse and a blood pressure of
124/60. Physical examination was unremarkable except for
ecchymosis in the left periorbital region. Relevant lab reports
produced the following results: MCV 131FL, platelet count
82,000/mm3, AST 176IU/L, alkaline phosphatase 140IU/L,
ALT 104IU/L, albumin 3.2g/dL, and INR 1.3. Serum potas-
sium, magnesium, corrected calcium, and cardiac enzymes
were within normal range. The patient’s chest X-ray was
unremarkable. EKG recorded 14 months prior to the ER pre-
sentation showed sinus rhythm and QTc 455ms (Figure 1).
The initial EKG on presentation showed ventricular
bigeminy (Figure 2) with QTc 550ms. In the ER, he devel-
oped two episodes of TdP (Figure 3) each resolving spon-
taneously, although the patient became unconscious for
approximately two minutes during each episode. He was
given 2g Magnesium IV and Amiodarone IV push 150mg
twice.ThepatientwastransferredtocardiacICU.HIVmedi-
cations were switched to raltegravir, emtricitabine/tenofovir;
methadone was discontinued. Three days later, he devel-
oped sinus bradycardia at 38beats per min (bpm) with
QTc 571ms (Figure 4). To shorten his QTc and prevent
further episodes of TdP, the patient underwent a temporary
pacemaker insertion and was paced at a rate of 100bpm
(Figure 5). After two days, his QTc slowly decreased and
sinus bradycardia resolved. 23 days following the modiﬁca-
tion of the medications administered to the patient, the EKG
still exhibited prolonged QTc (Figure 6). As the patient was
considered at high risk to develop TdP, he underwent an
implantable cardioverter deﬁbrillator (ICD) placement. He
is currently being followed with no further episodes of TdP.
2. Discussion
TdP belongs to a group of polymorphic ventricular tachy-
cardia characterized by varying QRS amplitudes that appear2 Cardiology Research and Practice
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Figure 1: Baseline EKG was acquired about 14 months prior to the syncope episodes. QTc 455ms.
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Figure 2: Initial 12 lead EKG in emergency room showing ventricular bigeminy. QTc was 550ms.
Figure 3: EKG tracing in emergency room showed short-long-short sequence of RR cycle followed by TdP. The patient had two episodes of
syncope while he had TdP. The above two tracings are from one of the two episodes.
to twist around an isoelectric line in the setting of long QTc
as revealed in this patient’s baseline EKG. TdP is commonly
preceded by long-short R-R cycle which is followed by
a late premature ventricular complex. Often, early after
depolarization manifested as T-U waves in EKG precede TdP.
In patients with prolonged QTc, the presence of pathological
T-U waves (Figure 6) might be the only warning sign of
imminent TdP [1].
Very often, the cause of TdP is multifactorial. The com-
mon risk factors of TdP include (a) female gender, (b) heart
disease, (c) electrolyte abnormalities, (d) bradyarrhythmias,
(e) stroke, and (f) a signiﬁcant universe of drugs that lead
to QT prolongation [2–4]. The upper limit of the duration
of QTc is often considered to be 430ms for adult males and
450ms for adult females, with a normal range of plus or
minus 15 percent. QTc prolongation is deﬁned as a QTc
of more than 450ms for adult males and 470ms for adult
females [5]. Studies have shown that QTc prolongation is an
independent predictor of cardiovascular mortality, especially
from ventricular arrhythmias such as TdP [6].
There is an increased prevalence of QTc prolongation
in patients with active HIV infection. Sani and OkeahialamCardiology Research and Practice 3
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Figure 4: Sinus bradycardia with heart rate of 38beats per minute occurred three days after admission. QTc 571ms. Also noted are
pathological T-U waves.
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Figure 5: Intravenous temporary pace maker was inserted for sinus bradycardia with long QTc. To prevent TdP, pacing rate was set at
100beats per minute.
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Figure 6: 23 days after admission, the EKG showed a QTc of 492ms prior to ICD placement. The pathological T-U waves are no longer seen.
showed that prolonged QTc was present in 28% of such
patients. In patients with AIDS, the prevalence increased to
45% [7]. In patients with HIV and autonomic neuropathy,
the prevalence of QTc prolongation is reported to be 65%
[8]. The exact reason for such correlation between QTc
prolongation and HIV infection is still a topic of debate.
But chronic HIV infection itself and many drugs used to
treat HIV and other opportunistic infections are plausible
explanations. In contrast, Charbit et al. suggested that QTc
prolongation is related to the duration of a patient’s HIV
infection rather than medications used during the treatment
of HIV or associated opportunistic infections [9]. Protease
inhibitors (PIs) are a group of medications implicated in
QTc prolongation because of the in vitro inhibition of4 Cardiology Research and Practice
the hERG (human ether-a-go-go-related gene) current [10].
But Charbit et al. concluded that protease inhibitors are not
independently associated with QTc prolongation [9].
Methadone is a very frequently used drug in the manage-
ment of pain and heroin addiction. Methadone causes the
blockade of hERG current and causes clinically signiﬁcant
QTc prolongation. Martell et al. found a 10.8ms increase
in QTc within 2 months of starting methadone in a group
of heroin users [11]. The prevalence of methadone-induced
QTc prolongation ranges between 16% and 33%, and this
can happen within a wide dose range of methadone (29–
1690mg/day)[12].Butmethadonedoseslessthan40mg/day
do not commonly cause QTC prolongation [13]. QTc pro-
longation caused by methadone is dose dependant and often
recent dose escalation is associated with TdP. Methadone
is metabolized by CYP3A4, which is also induced by PIs.
Patients, when started on PIs, might require escalation of
the methadone dose for symptom control which can further
prolong QTc. Methadone is also known to cause appearance
of pathological U waves in EKG which may be an indicator
of imminent TdP in some cases [14].
Hepatitis C is indicated as an independent risk factor
for QTc prolongation. Nordin et al. investigated the impact
of Hepatitis C and HIV coinfection on QTc prolongation
and suggested that hepatitis C co-infection nearly doubled
the risk of QTc prolongation in HIV positive patients. Liver
cirrhosis, low albumin, and high AST predict QTc prolon-
gation. These three factors tend to cluster with Hepatitis
C which explains the increased risk of QTc prolongation
associated with Hepatitis C infection [15].
The above case shows how multiple contributing factors
can cumulatively cause TdP in patients who already are at
risk due to genetic predisposition. This patient had a long
QTc to start with and also had HIV and Hepatitis C/liver
disease. He also was on antiretroviral medications for 10
years. Methadone dose escalation might have prolonged the
QTc further and caused appearance of T-U waves. In this
setting, a critically timed premature complex triggered oﬀ
TdP.Asthepatienthadmultipleriskfactorsandcontinuedto
have an abnormal QTc despite changing medications, he was
considered to be at high risk for further development of TdP,
and the decision of utilizing an ICD was made.
This case also highlights the need for carefully mon-
itoring susceptible patients treated with methadone for
potentially dangerous QT prolongation which can occur
even after the patient has been on therapy for some
time. Patients should also be made aware of relevant drug
interactions and the importance of reporting episodes of
dizziness or near syncope. Recent guidelines suggest getting
a baseline EKG before starting patients on methadone. After
initiationoftherapy,EKGshouldberepeatedtolookforQTc
prolongation within one month and then annually even if
patients are asymptomatic. Discontinuation of methadone
s h o u l db ec o n s i d e r e di fQ T c> 500ms [16].
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